We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,098.00
Bid: 12,096.00
Ask: 12,100.00
Change: 110.00 (0.92%)
Spread: 4.00 (0.033%)
Open: 12,254.00
High: 12,256.00
Low: 12,052.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

'Pivotal moment' as Britain set to roll out AstraZeneca vaccine

Mon, 04th Jan 2021 00:01

LONDON, Jan 4 (Reuters) - Britain will become the first
country to roll out the low cost and easily transportable
AstraZeneca and Oxford University COVID-19 vaccine on
Monday, another step forward in the global response to the
pandemic.

Six hospitals in England will administer the first of around
530,000 doses Britain has ready. The programme will be expanded
to hundreds of other British sites in the coming days, and the
government hopes it will deliver tens of millions of doses
within months.

"This is a pivotal moment in our fight against this awful
virus and I hope it provides renewed hope to everybody that the
end of this pandemic is in sight," health minister Matt Hancock
said in a statement.

Last month Britain became the first country to use a
different vaccine produced by Pfizer and BioNTech
, which has to be stored at very low temperatures.
Britain has so far injected around one million people with it.

The Oxford/AstraZeneca vaccine is cheaper and can be stored
at fridge temperature, which makes it easier to transport and
use. India approved the vaccine on Sunday for emergency use.

Cases of COVID-19 in Britain have risen sharply in recent
weeks, fuelled by a new and more transmissible variant of the
virus. On Sunday there were nearly 55,000 new cases and in total
more than 75,000 people in the country have died with COVID-19
during the pandemic - the second highest toll in Europe.

While the government has been keen to hail its vaccination
programme as the furthest advanced in the world, it has had to
balance the optimism of that message and plead with the public
to stick to rules to prevent new infections.

Prime Minister Boris Johnson said on Sunday that tougher
restrictions were likely to be introduced, even with millions of
citizens already living under the strictest tier of rules.

The spread of the variant virus has also forced the
government to change its approach to vaccination. Britain is now
prioritising getting a first dose of a vaccine to as many people
as possible over giving second doses. Delaying the distribution
of second shots should help stretch the supply.

The change of strategy has drawn criticism from some British
doctors.
(Reporting by William James; Editing by Susan Fenton)

More News
Today 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
Today 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
Today 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.